Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
11.61
+0.28 (2.47%)
Mar 6, 2026, 12:49 PM EST - Market open
Crescent Biopharma Analyst Ratings
Total Analysts
6
Consensus Rating
Strong Buy
Price Target
$26.67
Upside
+129.72%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $25 → $22 | Strong Buy | Maintains | $25 → $22 | +89.49% | Mar 2, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +201.46% | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +115.33% | Aug 27, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +123.94% | Aug 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +115.33% | Aug 11, 2025 |
| Wedbush | Wedbush | Buy Initiates $27 | Buy | Initiates | $27 | +132.56% | Jul 14, 2025 |
| Stifel | Stifel | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +141.17% | Jun 25, 2025 |
| LifeSci Capital | LifeSci Capital | Buy Initiates $22 | Buy | Initiates | $22 | +89.49% | Jun 18, 2025 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 15, 2021 |
| Raymond James | Raymond James | Buy Maintains $285 → $270 | Buy | Maintains | $285 → $270 | +2,225.58% | Aug 6, 2021 |
| Raymond James | Raymond James | Buy Maintains $270 → $285 | Buy | Maintains | $270 → $285 | +2,354.78% | Apr 29, 2021 |
| Piper Sandler | Piper Sandler | Buy Initiates $225 | Buy | Initiates | $225 | +1,837.98% | Feb 10, 2021 |
| Raymond James | Raymond James | Buy Maintains $300 → $270 | Buy | Maintains | $300 → $270 | +2,225.58% | Feb 4, 2021 |
| B. Riley Securities | B. Riley Securities | Strong Buy → Hold Downgrades $660 → $188 | Strong Buy → Hold | Downgrades | $660 → $188 | +1,514.99% | Jun 21, 2018 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $285 → $735 | Strong Buy | Maintains | $285 → $735 | +6,230.75% | Feb 12, 2018 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $150 → $1,125 | Strong Buy | Maintains | $150 → $1,125 | +9,589.92% | Feb 9, 2018 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.